Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
In Phase II clinical trials in adults with overweight or obesity, once-daily orforglipron led to 9-15% mean weight loss at 36 weeks, with a GI tolerability profile typical of the class
Enter vial size, bacteriostatic water volume, and target study dose to see the resulting concentration and draw volume on a U-100 insulin syringe
All products / Type / Easy Pen Retatrutide 10mg Easy Pen Triple GLP-1/GIP/glucagon agonist weight, glycemic & metabolic research SKU: EP-RET-10-1 Format Easy Pen Dosage 0.05mg per click Capacity 10 mg Potential benefits Weight-reduction research Glycemic-control research Liver-fat & liver-health research Cardiometabolic-marker research Body-composition research Weekly subcutaneous dosing In clinical trials, Retatrutide showed among the highest weight-reduction results recorded in clinical research for a non-surgical agent, while also addressing underlying drivers of metabolic disease
According to the Centers for Disease Control and Prevention (CDC), acetaminophen-related liver injury accounts for nearly 50% of all acute liver failure cases in the United States
US$ 25.32
US$ 23.86
US$ 21.08
US$ 23.11
